# HLB Innovation CAR-T Therapy Shows Response in 4 of 5 Lymphoma Patients

> HLB Innovation's CAR-T therapy SynKIR-310 achieved 80% response rate in relapsed lymphoma patients at ASH 2026 presentation.
- Title: HLB Innovation CAR-T Therapy Shows Response in 4 of 5…
- Summary: HLB Innovation's CAR-T therapy SynKIR-310 achieved 80% response rate in relapsed lymphoma patients at ASH 2026 presentation. HLB Innovation's US subsidiary…
- Keywords: hlb innovation, verismo therapeutics, synkir-310, car-t therapy, lymphoma, ash 2026, kir-car platform, relapsed lymphoma, phase 1 trial, markets, BigGo Finance
- Source: BigGo Finance — https://finance.biggo.com/news/a48d0ba4-b561-44f3-970a-2bb23b2cd701
- Author: BigGo Finance
- Published: 2026-11-05T02:06:11+00:00
- Read time: 1 min
- Topics: hlb innovation, verismo therapeutics, synkir-310, car-t therapy, lymphoma, ash 2026, kir-car platform, relapsed lymphoma, phase 1 trial, finance, markets
## Verismo Therapeutics Results
Verismo Therapeutics, the US subsidiary of South Korea's HLB Innovation, disclosed interim Phase 1 results for its relapsed/refractory B-cell non-Hodgkin lymphoma treatment SynKIR-310.
## Response Rate Achieved
Four of five evaluable patients responded, with three achieving complete responses and no cytokine release syndrome or ICANS reported.
## Safety Profile
None of the six patients in the first two dose cohorts reported cytokine release syndrome or ICANS, and no dose-limiting toxicities were observed.
## ASH 2026 Presentation
The data will be presented orally at the American Society of Hematology annual meeting (ASH 2026) in New Orleans on December 12.
## KIR-CAR Platform
Brian Kim, CEO and co-founder, described KIR-CAR as a proprietary platform to reduce excessive immune response and early T-cell exhaustion in CAR-T therapies.
## South Korean Companies Presenting
South Korea's LigaChem Biosciences, GC Cell, and Curocell will also present clinical results for blood cancer therapies at ASH 2026.
## Next Steps for Verismo
Verismo plans to disclose third cohort results and pharmacokinetic data at ASH 2026 to confirm dose-response relationship.
## Key takeaway

HLB Innovation's US subsidiary Verismo Therapeutics reported 80% objective response rate for its CAR-T therapy SynKIR-310 in relapsed lymphoma patients.